A Comparison of Budesonide with Prednisolone for Active Crohn's Disease
- 29 September 1994
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 331 (13) , 842-845
- https://doi.org/10.1056/nejm199409293311304
Abstract
Patients with active Crohn's disease are often treated with corticosteroids, but the treatment has many side effects. Budesonide is a potent, well-absorbed corticosteroid, but because of a high rate of first-pass metabolism in the liver, its systemic bioavailability is low.Keywords
This publication has 13 references indexed in Scilit:
- Oral Budesonide for Active Crohn's DiseaseNew England Journal of Medicine, 1994
- Oral budesonide in active Crohn's diseaseAlimentary Pharmacology & Therapeutics, 1993
- Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trialGastroenterology, 1993
- Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis.Gut, 1993
- BudesonideDrugs, 1992
- Budesonide Enema in Distal Ulcerative Colitis: a Randomized Dose-Response Trial with Prednisolone Enema as Positive ControlScandinavian Journal of Gastroenterology, 1991
- Overview of Newer Glucocorticosteroid Preparations for Inflammatory Bowel DiseaseCanadian Journal of Gastroenterology and Hepatology, 1990
- Transit of pharmaceutical dosage forms through the small intestine.Gut, 1986
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980
- A quantitative assay of cortisol in human plasma by high performance liquid chromatography using a selective chemically bonded stationary phaseClinica Chimica Acta; International Journal of Clinical Chemistry, 1977